EA013400B1 - Method for treating tumor diseases - Google Patents

Abstract

The invention relates to medicine and can be used for treating malignant and benign tumors. A method for treating tumor diseases involves administering Jungar monkshood based preparation into patient organism during the whole course of treatment divided to three steps, duration of which is 20 days, at the first step the Jungar monkshood based preparation is administered in daily increasing doses from 20 ng to 400 ng, at the second step administration is continued with 400 ng doses and additionally administer into patient organism a highly molecular regulatory protein of transforming growth factor family (TGF- β), at the third step the Jungar monkshood based preparation is further administered gradually reducing the dose from 400 ng to 20 ng. During the first step and at the end of the third step an immunomodulator is administered activating antitumor and antiviral activity of the immune system, wherein during the course of treatment phyto preparations are additionally administered including diuretic and cholagogic collections, antidepressants, antiparasitic collections of medicinal plants and/or preparations.

Description

The invention relates to medicine and can be used for the treatment of malignant and benign tumor formations.

There is a method of treating oncological diseases, which includes taking an alcoholic tincture of the red mushroom, which starts with a dose of 750 mg and increases each subsequent dose by 1012%, additionally takes 40-60% alcoholic tincture of the Jungar aconite root at a dose of 750 mg and increases it by 7- 10% daily, then after 5-15 minutes they take 30-50% alcoholic tincture of hemlock spotted herb at a dose of 750 mg and increase it by 7-10% at each subsequent dose, then dry Pallas euphorbia at a dose of 0.04-0, 1 and wash it down with 50 ml of the first collection of decoction containing mistletoe herb and celandine herb with a 1: 2 ratio of components, after which 30-50% alcoholic tincture of echinacea is taken in a dose of 5 ml, followed by increasing the dose to 12 ml, and 50 ml of the second collection of yarrow ordinary, grass water pepper, grass wormwood with a ratio of 2: 1: 1, then 50 ml of the third collection, including root berry thickener; 1, for those taking 750 mg of 70-96% alcohol tincture of propolis, a course of treatment is carried out 1-4 times a day, for 1.5-6 months, 2 times a year (see RF patent №2028808, cl. A61K 35/78, 1995).

Analysis of the known method of treating oncological diseases shows that potent agents that have already proven themselves in various phytotherapeutic schemes for the treatment of oncological diseases and possessing high antitumor activity are used for its implementation. However, in this method of treatment a very large amount of alkaloids is injected into the patient’s body, which can lead to disturbances in the work of the cardiovascular system. Prolonged use of drugs that are toxic in the phytocombination may result in damage to other, non-susceptible organs. In addition, a number of these drugs has a genotoxic effect.

All this reduces the effectiveness of treatment and imposes restrictions on its use.

There is also known a method of treating oncological diseases, according to which an aconite Jungar extract is injected into the patient's body, and the patient begins taking the drug with the minimum dose (the specific value of the minimum dose, the maximum dose, as well as the pattern of increasing its intake from minimum to maximum and decrease from maximum to minimum during the course of treatment depends on the type of disease, the patient's condition, the degree of development of the disease). Every day, the dose of aconite is increased until it reaches the maximum set value. Then in the patient's body for a certain time, the maximum doses of the drug are administered, and then the dose every day is gradually reduced to the minimum value. During the period of taking maximum doses of the drug based on aconite Jungar, a high molecular weight protein of the ΤΟΡ-β family is additionally introduced into the patient's body.

The course of treatment is two months. During the first 20 days of treatment, the patient is given daily an extract of Jungar aconite, starting from 120 ng of aconitine (first day) with a constant increase in dose to 2.4 μg (twentieth day).

For the next 20 days, the aconite Jungar extract is co-administered daily into the patient's body at the rate of the maximum dose (2.4 μg) and the high molecular weight protein of the ΤΟΡ-β family with a single dose of up to 300 μg.

For the next 20 days, the aconite Jungar extract is administered daily to the patient, starting at 2.4 mcg (first day), constantly reducing the dose to 120 ng (the twentieth day).

The combined use of drugs based on aconite of the Dzungarian and high molecular weight protein of the-β family produces a strong synergistic effect, manifested in the disintegration of the tumor mass. In addition, the combined use of these drugs helps to overcome the shortcomings of each of them, used separately - the relatively high toxicity of aconite tinctures and the possible ambiguity of the action of protein preparations (see RF Patent No. 2259210, А61К 35/78, 2003) .

As a result of consideration of the known method, it should be noted that it is not sufficiently effective in the treatment of advanced stages (3 and 4) of oncological diseases, and given that the drugs used in it have rather high toxicity, side effects may occur during the disintegration of tumors.

The present invention is to develop a method for the treatment of tumor diseases, allowing to increase the effectiveness of the treatment of both malignant and benign tumors, as well as reduce side effects in the process of tumor decay.

The task is ensured by the fact that in the method of treating tumor diseases, including the introduction into the patient's body of a drug based on Jungar aconite during the entire course of treatment, the treatment course is divided into three stages, the first of which is administered in a constantly increasing dose of Aconite Jungar. from minimum to maximum, in the second stage, continue to take the drug in maximum doses and additionally injected into the patient's body

- 1 013400 high-molecular regulatory protein of the ΤΟΕ-β family, and at the third stage they continue to take the drug based on Jungar aconite, constantly reducing its dose from the maximum to the minimum, it is essential that at the beginning of the first and at the end of the third stage of treatment an immunomodulator is introduced that activates the antitumor and antiviral activity of the immune system, while phytopreparations are additionally administered to the patient during the course of treatment, which use diuretic and elchegonnye charges, antidepressants and anti charges medicinal plants and / or drugs.

The manufacturing techniques and applications of each of the used preparations are known, they are not the subject of patent protection and therefore are not disclosed in the application materials.

When conducting patent studies, no solutions were found that were identical to the claimed one, and therefore, the claimed invention meets the criterion of "novelty."

We believe that the essence of the claimed invention should not be explicitly known solutions, and therefore, the claimed method meets the criterion of "inventive step".

We believe that the information set forth in the application materials is sufficient for the practical use of the invention.

A method for the treatment of tumor diseases is as follows.

The course is designed for 60 days (two months). Depending on the type and stage of the disease, patients may be assigned to several repetitive courses. As practice has shown, the number of treatment courses usually does not exceed four.

Each course is divided into three twenty-day (six week-days) and is based on the taking of complementary drugs, which, with the following reception sequence, provide a high therapeutic effect, consisting in suppressing the growth and destruction of tumor tissue;

suppression of tumor metastasis;

suppression of associated parasitic diseases;

increasing the general nonspecific resistance of the organism to adverse factors; elimination of depression;

enhance excretory functions of the body;

reducing body toxicity.

During the course of treatment, the first two ten-day patients receive the tincture of Jungar aconite. The reception of this drug is carried out in gradually and evenly increasing doses from the minimum to the maximum. The minimum dose of the drug with which to start taking depends on the stage and type of the disease, on the weight of the patient. Usually this dose, which is the minimum, on the first day of administration corresponds to 20 μl (one drop), and the maximum dose corresponds to 400 μl (20 drops) on the twentieth day of administration.

Dzhungar aconite tincture, as is known to specialists, is the most powerful and practically universal preparation with pronounced antitumor properties and contains alkaloids (mainly aconitine) with high biological activity. The use of tincture of Jungar aconite allows suppressing the activity of oncogenes, in particular, in the process of metastasis. The alkaloids contained in the preparation have a cytotoxic effect, which consists in stopping the division of tumor cells.

The use of tincture in gradually increasing doses allows the body to adapt to this drug and reduce the possible negative impact on the body of its toxic components.

It is very important to increase the effectiveness of treatment that at the beginning of treatment an immunomodulator is injected into the patient’s body, depending on the type and stage of the disease, as well as on the patient’s weight from 25 to 50 μg.

The use of an immunomodulator at the beginning of a course of treatment contributes to an increase in the activity of the immune system.

Immunomodulators that can be used for this treatment method are known to those skilled in the art. So as an immunomodulator can be used an aqueous extract of the muscles and skin of reptiles squad squad. An immunomodulator can be obtained as follows.

Place 50 g of the prepared material in a container and pour 0.2 l of distilled water. The contents of the container are brought to a boil and boil for 60 minutes. Remove the hydrophobic impurities with chloroform. Shake the product on a separating column, separate the water and chloroform, and then carry out the lyophilic drying of the obtained extract. The product yield is 1 g.

This immunomodulator is characterized by stimulation of the production of cytokines IFNa, β, γ, TNF, as well as interleukins 1β, which are involved in the anti-infective defense of the body and the activation of adaptive immunity. IFNa, β, γ and TNF are activators of natural killer cells (ΝΚ-cells), which are the basis of anticancer immunity.

The second two ten-days carry out a constant intake of tincture of Jungar aconite in poppy

- 2,013,400 of the maximum dose and additionally carry out injections of high-molecular regulatory protein of the TCE-β family in a single dose of approximately 300 μg of the drug. The specific value of the dose and duration of use depends on the type of disease, its stage, and the weight of the patient.

As a preparation of a high molecular weight regulatory protein, for example, activin, inhibin can be used.

The technology of obtaining regulatory protein and its action is known.

The regulatory protein has both direct and mediated antitumor activity. When acting on the immune system, it includes a mechanism for autoreproduction and induction of tumor necrosis factor. Under the action on tumor cells, the drug inhibits the activity of genes responsible for proliferation, and includes a differentiation mechanism, acting through a system of receptors and signal peptides entering the nucleus and regulating the transcription process directly.

The combined use of an immunomodulator (introduced at the first stage of a course of treatment) and a regulatory protein provides effective synergies in suppressing tumor growth.

The combined effect of tincture of aconite, immunomodulator and high-molecular regulatory protein of the TSR-β family in the second stage of treatment provides a powerful breakdown of tumor tissue.

At the third stage of treatment (the fifth and sixth ten days), the injections of the regulatory protein are stopped and the Jungar aconite tincture is taken, starting from the maximum dose (400 μl), gradually, as it is taken, reducing it to the minimum (20 μl).

A gradual decrease in the dose of Aconite Jungar tincture at this stage allows to ensure the absence of intoxication of the organism.

To improve immunity in order to suppress the associated inflammatory processes at the end of this stage, as described above, an immunomodulator is injected into the patient's body.

If the course did not ensure complete suppression of the tumor disease, repeat the course.

As practice has shown, this course is very effective in treating a wide range of tumor diseases, especially in the later stages of the disease. Its use does not cause any complications.

The course of the proposed treatment is more effective if it is additionally accompanied by the administration of medicinal plants and / or preparations.

During treatment, it is recommended to take additional antidepressants, diuretic and choleretic fees, as well as antiparasitic charges, the use of which is traditional.

So, during the third stage of the course of treatment, it is advisable to combine the reception of the Jungar aconite tincture with the use of herbal remedies, the purpose of which is to remove the atypical and tumor cells from the body of decomposition, reducing the body's intoxication.

As diuretic fees can be used fees, which contain the collection No. 1: lingonberry leaf; Kuril tea; bearberry; highlander; horsetail;

collection number 2: lingonberry leaf; highlander; peppermint; Hypericum perforatum; birch leaf.

As choleretic fees can be used collection number 1: chamomile flowers; dandelion roots; inflorescences of cumin sandy; Hypericum herb perforatum;

collection number 2: stinging nettle; sandy wren; oregano; wild rose (fruit); peppermint.

The following charges can be used as antidepressants:

collection number 1: allspice buds; bark of cinnamon tree; fruits of nutmeg fragrant; fruits of cardamom present; turmeric rhizomes long;

collection number 2: hawthorn; fireweed; viburnum (fruit); thyme; oregano; motherwort.

The following charges may be used as antiparasitic:

collection number 1: red root;

collection number 2: motherwort; oregano; tributary; evading peony; rhododendron is golden; birch (leaf); lingonberry (leaf); wheatgrass creeping (rhizome); burdock (leaf); black currant (leaf); wild rosemary (runaways); stinging nettle; narrow-leaved fireweed; horsetail; fir (foot).

The above does not mean that only these fees can be used for treatment. Experts know a large number of fees for use in the above purposes.

Preparation fees does not cause difficulties for specialists. Acceptance of these drugs is carried out in traditional doses, which are also known to specialists.

For the course of treatment, one teaspoon of the collection is brewed in a glass of boiling water. Intake of at least 1/3 cup.

Reception tincture aconite Jungar carried out once a day.

Studies have shown that the Karakol aconite has a similar effect as compared to the Dzhungar aconite tincture on the patient’s body;

- 3 013400 Rata almost interchangeable.

Reception of regulatory protein is carried out once a day during the second twenty-day course.

The procedure for taking an immunomodulator is described above.

To avoid habituation of the organism to the used herbal remedies, it is recommended to replace herbal remedies every other day for others that have a similar effect. So, if the first ten days of the course used drugs named collection No. 1 in the description, then collection No. 2 was used during the second ten-day period, collection No. 1 was used during the third ten-day, and so until the end of the course, that is, it is most appropriate to use : 1, 3, 5 ten days - fees № 1; 2, 4, 6 ten days - fees № 2.

When developing a course of treatment, the main condition was that the course can be really effective if it is aimed simultaneously at the etiology of the disease, its pathogenesis, individual symptoms and symptom complexes, as well as accompanying pathogenetic processes in the functioning of the main systems of vital activity of the organism.

The claimed method has been successfully used for the treatment of various tumor diseases such as bladder cancer, breast cancer, lung cancer, colon cancer, uterine cancer, prostate cancer, myeloma, leukemia.

The effectiveness of the treatment is confirmed by the following examples.

Patient U. Diagnosis of bladder cancer with tumor invasion beyond the bladder. State after surgical removal of the tumor, followed by polychemotherapy (3 courses). On the background of taking one proposed comprehensive course of taking drugs, stabilization of the tumor process was noted, and later - complete regression of the tumor. According to surveys, remission is third year. Signs of the return of the tumor is not marked.

Patient K. The diagnosis of bladder cancer stage II. State after surgical treatment with subsequent chemotherapy transurethally (I course). Then the patient underwent II course of treatment. Over the next 3 years according to the survey and clinical signs of relapse and metastasis is not observed. The patient feels quite satisfactory.

Patient G. Diagnosis of stage IV bladder cancer. State after 10 courses of chemotherapy (transurethally + systemic). Subsequently, several operations to remove a recurrent tumor. After the first course of treatment, the disintegration of the tumor was noted, and further its full regression. The decay products of the tumor were excreted in the urine; urination was accompanied by a strong fetid odor. Films and small pieces of a decaying tumor were visually present in the urine, and a sediment up to 3-4 cm thick was observed in each portion of urine. A similar state was observed until the end of the course of treatment. In order to consolidate the achieved result, the II course of treatment was carried out, after which, according to a survey (ultrasound + cystoscopy), a complete regression of the tumor conglomerate was noted.

Patient M. Diagnosis of cervical cancer (not operated). On the first course of treatment, minor bleeding opened and several large tumor conglomerates were rejected. A week later, another fragment of the tumor rejected. Control tests (ultrasound + gynecologist examination) registered the absence of a tumor in the patient. The general condition and well-being of the patient improved, gained in weight by 4 kg, does not present any complaints so far.

Patient I. Diagnosis teratoblastoma of the right ovary, twice operated. After each surgery, the tumor restored its former size (its size corresponded to the head of a newborn child); liver metastases were recorded. Further surgical intervention was considered inappropriate. After 3 courses of the proposed therapy, cessation of tumor growth and metastasis was noted. In the future, the patient underwent radical surgical treatment. Currently, the patient leads an active lifestyle (5 years).

Patient A. The diagnosis of leiomisarcoma with liver damage to more than 2/3 of the organ. In the small pelvis tumor conglomerate. The case was declared inoperable, special treatment was denied to the patient - he was sent in serious condition to go home for symptomatic treatment. Passed three courses of the proposed therapy. By the end of the second course of treatment, the rapid disintegration of the tumor mass began to be noted, the decay products were excreted with fecal masses, a characteristic fetid odor. The decay process was accompanied by fever (I to 39 °). By the sixth month of treatment, recovery of the normal structure of the liver and the absence of metastases were noted clinically and according to ultrasound diagnostics. The main node (initially having a large size) turned into a thin-walled fluid formation (such as a cyst). Distant metastases were not detected. The patient rekindled his interest in active life, his state of health and appetite improved, and there was hope for recovery. The possibility of evacuating the contents from the bladder was considered, however, a spontaneous rupture of the cyst occurred and the patient died of manifestations of peritonitis. It should be noted that according to the pathological findings of the patient, there were no signs of metastasis in all organs.

We also observed positive results in the treatment of colorectal cancer, ovarian cancer, lung cancer, and kidney cancer.

- 4 013400

Claims (2)

CLAIM 1. A method of treating tumor diseases, including the introduction into the patient's body of a drug based on Jungar aconite during the entire course of treatment, and the course of treatment is divided into three stages, the duration of each of which is 20 days, at the first stage the drug based on Jungar aconite is constantly administered increasing doses from 20 to 400 μl, in the second stage continue to receive the drug in doses of 400 μl and additionally injected into the patient's body a high molecular weight regulatory protein of the family of transforming growth factors (ΤΟΕ-β), and at the third stage they continue to take the drug on the basis of Jungar aconite, constantly reducing its dose from 400 to 20 μl, characterized in that at the beginning of the first and at the end of the third stage of treatment, an immunomodulator activating the antitumor and antiviral activity of the immune system. 2. A method of treating tumor diseases according to claim 1, characterized in that during the course of treatment, phytopreparations are additionally introduced into the patient's body, which use diuretic and choleretic charges, antidepressants and antiparasitic preparations of medicinal plants and / or drugs. ABOUT